BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) – A Strong Growth Candidate Meeting Minervini’s Criteria

BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) has been identified as a high-growth momentum stock that aligns with Mark Minervini’s Trend Template. The company, a biotechnology firm specializing in treatments for rare diseases, demonstrates strong technical and fundamental characteristics that make it a compelling candidate for growth-focused investors.

Technical Strength: Meeting Minervini’s Trend Template

BCRX satisfies the key technical criteria outlined in Minervini’s strategy, which focuses on stocks in strong uptrends:

• Price Above Key Moving Averages: The stock trades at $10.73, well above its 50-day ($8.74), 150-day ($8.16), and 200-day ($8.07) moving averages.
• Upward-Trending Averages: Both the 150-day and 200-day moving averages are rising, confirming long-term strength.
• Relative Strength: With a ChartMill Relative Strength (CRS) score of 95.42, BCRX outperforms 95% of the market.
• Price Near 52-Week High: At $10.73, the stock is within 4% of its 52-week high ($11.15) and 81% above its 52-week low ($5.92).

These factors indicate a stock in a sustained uptrend with strong momentum—a hallmark of Minervini’s high-probability setups.

Fundamental Growth Drivers

Beyond technicals, BCRX exhibits accelerating growth metrics that appeal to high-growth investors:

• Revenue Growth: Quarterly revenue growth stands at 56.9% year-over-year, with a trailing twelve-month (TTM) revenue increase of 41.7%.
• Earnings Momentum: EPS growth surged 100% in the latest quarter, with analysts revising next-year EPS estimates upward by 134% over the past three months.
• Profitability Improvement: The company recently turned profitable, with a positive profit margin in its latest quarter (2.2%).
• Pipeline Potential: BCRX’s lead product, ORLADEYO, treats hereditary angioedema (HAE), a rare condition with limited competition, providing a durable revenue runway.

Technical Report Summary

BCRX holds a perfect 10/10 technical rating from ChartMill, reflecting its strong trend and market leadership. Key takeaways from the report:

• The stock is trading near the top of its recent range ($9.59–$11.15), with resistance at $11.04.
• Support levels are firm at $9.84 (daily) and $7.25 (weekly trendline).
• The setup rating of 6 suggests consolidation before a potential breakout above $11.05.

For a deeper analysis, review the full technical report here.

Our High Growth Momentum + Trend Template screener identifies more stocks with similar growth and technical strength.

Disclaimer

This is not investment advice. Always conduct your own research and consider risk tolerance before making investment decisions.